UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Regulation and function of apoptosis signal-regulating kinase 1 in rheumatoid arthritis

Biochemical pharmacology, 2018-05, Vol.151, p.282-290

2018

Volltextzugriff (PDF)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Annals of the rheumatic diseases, 2021-07, Vol.80 (7), p.865-875

2021

Volltextzugriff (PDF)

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice

JCI insight, 2018-10, Vol.3 (19)

2018

Volltextzugriff (PDF)

Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

BMC rheumatology, 2021-03, Vol.5 (1), p.15-15, Article 15

2021

Volltextzugriff (PDF)

Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

Journal of medicinal chemistry, 2014-05, Vol.57 (9), p.3856-3873

2014

Volltextzugriff (PDF)

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

Nature chemical biology, 2011-01, Vol.7 (1), p.41-50

2011

Volltextzugriff (PDF)

B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies

International reviews of immunology, 2013-08, Vol.32 (4), p.397-427

2013

Volltextzugriff (PDF)

Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases

ACS medicinal chemistry letters, 2020-04, Vol.11 (4), p.506-513

2020

Volltextzugriff (PDF)

Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis

Thrombosis research, 2018-10, Vol.170, p.109-118

2018

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

Clinical drug investigation, 2017-02, Vol.37 (2), p.195-205

2017

Volltextzugriff (PDF)

Abstract 4205: Mass-spectroscopy phosphorylation profiling identified differential activation of signaling molecules via spleen tyrosine kinase in B-cell receptor signaling and stromal cell stimulation in DLBCL and CLL cells that are inhibited by GS-9973

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4205-4205

2014

Volltextzugriff (PDF)

Abstract 26: Evaluation of the safety, pharmacokinetics and pharmacodynamics of GS-9973, a novel SYK inhibitor, and GS-1101, a novel PI3Kδ inhibitor, when administered alone or in combination in humans

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.26-26

2013

Volltextzugriff (PDF)

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Blood, 2013-11, Vol.122 (21), p.1634-1634

2013

Volltextzugriff (PDF)

Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice

Science translational medicine, 2020-05, Vol.12 (545)

2020

Volltextzugriff (PDF)

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Blood, 2016-05, Vol.127 (20), p.2411-2415

2016

Volltextzugriff (PDF)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3937-3946

2020

Volltextzugriff (PDF)

ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP

Nature communications, 2019-07, Vol.10 (1), p.3304-15, Article 3304

2019

Volltextzugriff (PDF)

Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis

Science signaling, 2012-11, Vol.5 (249), p.ra79

2012

Volltextzugriff (PDF)

Remodeling microglia to a protective phenotype in Parkinson’s disease?

Neuroscience letters, 2020-09, Vol.735, p.135164, Article 135164

2020

Volltextzugriff (PDF)

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

The lancet oncology, 2019-06, Vol.20 (6), p.781-794

2019

Volltextzugriff (PDF)

Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease

The Journal of experimental medicine, 2023-05, Vol.220 (5)

2023

Volltextzugriff (PDF)

Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy

The Journal of pharmacology and experimental therapeutics, 2011-07, Vol.338 (1), p.154-163

2011

Volltextzugriff (PDF)

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib

Therapeutic Advances in Hematology, 2016-06, Vol.7 (3), p.157-170

2016

Volltextzugriff (PDF)

Arf6 controls retromer traffic and intracellular cholesterol distribution via a phosphoinositide-based mechanism

Nature communications, 2016-06, Vol.7 (1), p.11919-11919, Article 11919

2016

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Englisch
(69)

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Life Sciences & Biomedicine
(43)
Humans
(25)
Animals
(20)
Female
(13)
Mice
(12)
Male
(9)
Adult
(8)
Kinases
(8)
Middle Aged
(8)
Oncology
(8)
Pharmacology & Pharmacy
(8)
Rats
(8)
Cell Biology
(7)
Immunology
(6)
Life Sciences
(6)
Patients
(6)
Protein Kinase Inhibitors - Pharmacology
(6)
Signal Transduction
(6)
Aged
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Regulation and function of apoptosis signal-regulating kinase 1 in rheumatoid arthritis

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

SYK inhibitor entospletinib prevents ocular and skin GVHD in mice

Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies

Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases

Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

Abstract 4205: Mass-spectroscopy phosphorylation profiling identified differential activation of signaling molecules via spleen tyrosine kinase in B-cell receptor signaling and stromal cell stimulation in DLBCL and CLL cells that are inhibited by GS-9973

Abstract 26: Evaluation of the safety, pharmacokinetics and pharmacodynamics of GS-9973, a novel SYK inhibitor, and GS-1101, a novel PI3Kδ inhibitor, when administered alone or in combination in humans

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP

Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis

Remodeling microglia to a protective phenotype in Parkinson’s disease?

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease

Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib

Arf6 controls retromer traffic and intracellular cholesterol distribution via a phosphoinositide-based mechanism

Suchergebnisse filtern